Alisporivir program rights returned to Debiopharm

Debiopharm Group has regained all rights to Alisporivir, a cyclophilin inhibitor being investigated for the treatment of hepatitis C virus infection, as a result of a new agreement between the pharmaceutical company and Novartis, according to a news release from the company.

Alisporivir (DEB025, Debiopharm) is currently undergoing two phase 2 clinical trials of therapy without interferon for HCV, and has already been tested in over 2,000 patients, according to the release.

The release stated that Debiopharm and Novartis entered into a partnership for the development of alisporivir in January 2010, which allowed for the current transfer of ongoing alisporivir phase 2 clinical trials to Debiopharm. The new agreement also transfers all rights for HCV and other indications for the drug.


Labels: , , , ,